News Releases

Keyword Search

Aug-02-2021
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Aug-02-2021
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Jul-29-2021
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
Jul-01-2021
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
Jun-01-2021
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May-26-2021
Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May-19-2021
Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021
May-19-2021
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
May-17-2021
Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
May-06-2021
Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results